One study suggested that CBP/P300 BRD inhibition may lead to a more activated phenotype in CTLs, but did not report an increase in CTL frequency in the CT26 tumors, a colon cancer and “hot tumor” model known to have high lymphocyte infiltration and respond to ICB (76). This evidence concerns the gene CREBBP and colonic neoplasm.